Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of difluoromethylornithine (DFMO) with bortezomib in relapsed or refractory neuroblastoma has com…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) [Phase 2]
A pediatric MATCH phase 2 trial assessed olaparib in children with relapsed or refractory advanced solid tumors or non-Hodgkin lymphoma carr…
-
CLINICAL_TRIALS trial_result · 2024-04-24Clinical Trial Update: Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating palbociclib in relapsed or refractory pediatric tumors with activating alterations in cell cycle ge…
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma [Phase 2]
Phase 2 safety study evaluating dinutuximab combined with immunotherapy for neuroblastoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Molecular-Guided Therapy for Childhood Cancer [NA]
A completed clinical trial evaluating molecular-guided therapy for several childhood cancers, with results posted in April 2024.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]
Phase 1/2 clinical trial update on NK donor lymphocyte infusion following HLA-haploidentical HSCT; study status completed.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma [Phase 2]
Phase 2 trial of naxitamab plus GM-CSF in combination with intratumoral therapy in high-risk neuroblastoma was terminated; results posted in…
-
CLINICAL_TRIALS trial_result · 2024-02-13Clinical Trial Update: 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases [Phase 2, Phase 3]
Clinical trial update for 131I-omburtamab in neuroblastoma with CNS/leptomeningeal metastases shows terminated status with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma [Phase 1]
Phase 1 trial evaluating crizotinib with combination chemotherapy in younger patients with relapsed or refractory solid tumors or anaplastic…
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma [Phase 2]
A Phase 2 clinical trial evaluating CH14.18 1021 antibody and IL-2 after haploidentical stem cell transplant in children with relapsed neuro…
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients [Phase 1, Phase 2]
Clinical trial update on Copanlisib in pediatric patients with relapsed or refractory solid tumors or lymphoma, including neuroblastoma, wit…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma [Phase 3]
Phase 3 clinical trial evaluating induction chemoimmunotherapy in high-risk neuroblastoma; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. [Phase 4]
Phase 4 trial evaluating Naxitamab + GM-CSF with isotretinoin as maintenance therapy for high-risk neuroblastoma in first complete response.
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Racotumomab in Patients With High-risk Neuroblastoma [Phase 2]
Phase 2 clinical trial update for Racotumomab in high-risk neuroblastoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: European Low and Intermediate Risk Neuroblastoma Protocol [Phase 3]
Phase 3 clinical trial update for European protocol addressing low and intermediate risk pediatric neuroblastoma and neonatal suprarenal mas…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers [Phase 1, Phase 2]
Phase 1/2 trial investigating Hu3F8-BsAb for relapsed/refractory neuroblastoma and osteosarcoma terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 Pediatric MATCH trial evaluating Ulixertinib for MAPK-pathway-mutant tumors in children, including advanced solid tumors, Non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating bempegaldesleukin (BEMPEG) in combination with nivolumab in pediatric and young adult patients with recurrent o…
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma [Phase 2]
Phase 2 trial evaluating dinutuximab with sargramostim and combination chemotherapy for newly diagnosed high-risk neuroblastoma; results hav…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: Therapy for Children With Advanced Stage Neuroblastoma [Phase 2]
Phase 2 trial results for a therapy in children with advanced neuroblastoma have been completed and posted. The study was conducted under St…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects [Phase 2]
Phase 2 trial investigating iobenguane (131-I) with vorinostat for recurrent or progressive high-risk neuroblastoma; current status not disc…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas [Phase 1, Phase 2]
Phase 1/2 trial evaluating nivolumab with or without ipilimumab in younger patients with recurrent or refractory solid tumors or sarcomas; c…
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma [Phase 2]
Phase 2 clinical trial evaluating nifurtimox for refractory or relapsed neuroblastoma or medulloblastoma has completed and results were post…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
A Phase 2 pediatric MATCH trial evaluating selumetinib sulfate in relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, and hi…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating adavosertib in combination with irinotecan hydrochloride for relapsed or refractory solid tumors in younger patie…